甲状腺激素受体β激动剂HSK31679通过调节肠道微生物鞘脂缓解代谢功能障碍相关脂肪性肝病
本研究在无菌与无特定病原体小鼠中比较MGL-3196与HSK31679对MASH的改善作用,并对随机双盲安慰剂对照多次递增剂量队列(HSK31679组n=32,安慰剂组n=8)进行多组学分析,发现HSK31679经抑制肠道微生物葡萄糖神经酰胺合成酶促进MASH缓解,该酶活性可能作为疗效预测生物标志物。
要点
- HSK31679改善SPF小鼠MASH饮食诱导的脂肪性肝炎优于MGL-3196,但在GF小鼠中无此优势。
- HSK31679富集B. thetaiotaomicron,抑制微生物GCS对Cer(d18:1/16:0)和Cer(d18:1/24:1)的单葡萄糖基化。
- 粪便GCS活性高者接受160 mg HSK31679后外周CD8α+树突状细胞和MINCLE+巨噬细胞减少。
核心结论
- 肠道微生物是HSK31679疗效的关键,微生物GCS可作为MASH治疗反应的潜在预测生物标志物及基于微生物群治疗的新靶点。
研究设计与样本
- 比较MGL-3196与HSK31679在无菌(GF)和无特定病原体(SPF)小鼠中对MASH饮食诱导脂肪性肝炎的改善作用。
- 对随机、双盲、安慰剂对照多次递增剂量队列(HSK31679组n=32,安慰剂组n=8)进行微生物宏基因组、代谢组和单细胞RNA测序的交叉组学分析。
主要发现
- HSK31679改善SPF小鼠MASH饮食诱导的脂肪性肝炎优于MGL-3196,但在GF小鼠中无此优势。
- HSK31679组B. thetaiotaomicron相对丰度显著富集,损害GCS催化的微生物Cer(d18:1/16:0)和Cer(d18:1/24:1)单葡萄糖基化。
- 在GFBTΔGCS小鼠中MGL-3196与HSK31679对MASH缓解效果非劣,而在GFBTWT小鼠中HSK31679对脂肪性肝炎带来更优获益,归因于其对肠道微生物GCS的R123和Y401的空间位阻。
- 粪便GCS活性高的参与者接受160 mg HSK31679后,外周区室向免疫抑制龛转变,特征为CD8α+树突状细胞和MINCLE+巨噬细胞减少。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: As the first approved medication for metabolic dysfunction-associated steatohepatitis (MASH), the thyroid hormone receptor-β (THR-β) agonist MGL-3196 (resmetirom) has garnered much attention as a liver-directed, bioactive oral drug. However, studies on MGL-3196 have also identified remarkable heterogeneity of individual clinical efficacy and its interference with gut microbiota in host hepatoenteral circulation remains to be elucidated. METHODS: We compared MASH attenuation by MGL-3196 and its derivative drug HSK31679 between germ-free (GF) and specific-pathogen free (SPF) mice to evaluate the role of gut microbiota. Then cross-omics analyses of microbial metagenome, metabolome and single-cell RNA-sequencing were applied to a randomized, double-blind, placebo-controlled multiple ascending dose cohort receiving HSK31679 treatment (n = 32) or placebo (n = 8), to comprehensively investigate the altered gut microbiota metabolism and circulating immune signatures. RESULTS: HSK31679 outperformed MGL-3196 in ameliorating MASH diet-induced steatohepatitis of SPF mice but not GF mice. In the multiple ascending dose cohort of HSK31679, the relative abundance of B. thetaiotaomicron was significantly enriched, impairing glucosylceramide synthase (GCS)-catalyzed monoglucosylation of microbial Cer(d18:1/16:0) and Cer(d18:1/24:1). In contrast to the non-inferior effect of MGL-3196 and HSK31679 on MASH resolution in GFBTΔGCS mice, HSK31679 led to superior benefit on steatohepatitis in GFBTWT mice, due to its steric hindrance of R123 and Y401 of gut microbial GCS. For participants with high fecal GCS activity, the administration of 160 mg HSK31679 induced a shift in peripheral compartments towards an immunosuppressive niche, characterized by decreased CD8α+ dendritic cells and MINCLE+ macrophages. CONCLUSIONS: This study provided novel insights into the gut microbiota that are key to the efficacy of HSK31679 treatment, revealing microbial GCS as a potential predictive biomarker in MASH, as well as a new target for further microbiota-based treatment strategies for MASH. IMPACT AND IMPLICATIONS: Remarkable heterogeneity in individual clinical efficacy of thyroid hormone receptor-β agonists and their interferences with the microbiome in host hepatoenteral circulation are poorly understood. In our current germ-free mouse models and a randomized, double-blind, multiple-dose cohort study, we identified microbial glucosylceramide synthase as a key mechanistic node in the resolution of metabolic dysfunction-associated steatohepatitis. Microbial glucosylceramide synthase activity could be a predictive biomarker of response to HSK31679 treatment or a new target for microbiota-based therapeutics in metabolic dysfunction-associated steatohepatitis.
引用
- Zhang YH, Xie R, Dai CS, et al. Thyroid hormone receptor-beta agonist HSK31679 alleviates MASLD by modulating gut microbial sphingolipids. J Hepatol. 2024. PMID: 39181210. doi:10.1016/j.jhep.2024.08.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。